Sema (GLP-1 Receptor Agonist)

REGULATORY STATUS : READ BEFORE PROCEEDING Semaglutide is an FDA-approved prescription drug (NDA 209637, NDA 213051, NDA 215256) marketed as Ozempic, Rybelsus, and Wegovy by Novo Nordisk. It is NOT a research-use-only (RUO) compound. This document is a scientific reference resource providing registry-anchored pharmacological and regulatory information for educational, academic, and pharmaceutical research professional use only. This document does not constitute a product listing, does not represent an offer to supply semaglutide, and must not be construed as guidance for therapeutic, compounding, or clinical use. FDA declared the semaglutide shortage resolved on 21 February 2025 and has since intensified enforcement against compounders, telehealth platforms, and marketers of unapproved semaglutide products. Compounded or “research” semaglutide products are treated as high-risk and non-substitutes for approved medicines under 2025-2026 FDA policy. Consult a licensed healthcare provider and FDA.gov for approved use information.

PRODUCT OVERVIEW

Semaglutide is a long-acting, chemically modified glucagon-like peptide-1 (GLP-1) receptor agonist, classified as a GLP-1 receptor peptidomimetic agonist derived from human GLP-1 (7–37). Its peptide backbone, produced by yeast (Saccharomyces cerevisiae) fermentation and subsequently chemically modified, is 94% homologous to native human GLP-1.

Semaglutide is an FDA-approved prescription drug commercialised in multiple presentations: Ozempic (NDA 209637, subcutaneous and tablet), Rybelsus (NDA 213051, oral tablet), Wegovy (NDA 215256, subcutaneous and tablet, including Wegovy HD 7.2 mg approved March 2026). It is no longer a single-product opportunity but a platform franchise spanning metabolic, cardiovascular, renal, and liver indications. The IUPHAR/BPS Guide to Pharmacology and KEGG classify semaglutide within antidiabetic and anti-obesity drug pathways, mapping its actions onto incretin and energy-homeostasis modules. These cross-references reinforce that semaglutide is a well-characterised pharmaceutical agent rather than a generic “research peptide.”

DISCLAIMER:

• • Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited.
  • All the products you see on the website are being sold as a freeze dried powder, in a sealed sterile vial; and should be reconstituted.
    The product’s label clearly states the amount of product a vial contains; some products are offered in different variations.
  • The products we are selling come in a sealed vial but require additional lab equipment for proper testing.
  • Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.